Gallium Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 567.36%
(FY 2022)
- Profit 421.48%
(FY 2022)
- Ebitda -85.56%
(FY 2022)
- Net Worth 34.49%
(FY 2022)
- Total Assets 270.36%
(FY 2022)
About Gallium Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nitin Bhagwat and Sachin Natthuji serve as directors at the Company.
- CIN/LLPIN
U24304MH2017PTC301176
- Company No.
301176
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Oct 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationNagpur, Maharashtra
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Gallium Pharmaceuticals Private Limited offer?
Gallium Pharmaceuticals Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Cardiovascular Drugs & Medication, Cardiac Drugs, Common Disease Medicines, Pharmaceutical Tablets, Anti Infective Drugs & Medicines, Antifungal Cream, Ointment & Powder, Immunization & Vaccination Drugs, Vaccines.
Who are the key members and board of directors at Gallium Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitin Bhagwat  | Director | 26-Oct-2017 | Current |
| Sachin Natthuji | Director | 19-Apr-2018 | Current |
Financial Performance of Gallium Pharmaceuticals.
Gallium Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 567.36% increase. The company also saw a substantial improvement in profitability, with a 421.48% increase in profit. The company's net worth Soared by an impressive increase of 34.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gallium Pharmaceuticals?
In 2021, Gallium Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ozar Care Exim Private LimitedActive 5 years 6 monthsNitin Bhagwat and Sachin Natthuji are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gallium Pharmaceuticals?
Unlock and access historical data on people associated with Gallium Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gallium Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gallium Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
